Oragenics Inc
OGEN NYSE· Pharmaceutical Preparations
Last close · Oct 26, 2026
$0.40
KIRA · Stoqly’s AI analyst, in plain words
- Oragenics Inc lost $9.8M in fiscal 2025.
Market cap
$1.8M
P/E
0.4x
Revenue
—
Net income
−$9.8M
Free cash flow
—
Operating margin
—
Oragenics Inc in 30 seconds · fiscal 2025
Does it make a profit?
−$9.8M
No. It lost money last year.
How is the share priced?
0.4x
One share costs 0.4 times its yearly profit per share.
What Oragenics Inc does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 16, 2026
- Legal name
- ORAGENICS INC
- CIK
- 0001174940
Oragenics Inc · OGEN
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.1M | $0.1M | $0.0M | — | — |
| Revenue growth | — | 51.1% | −71.3% | — | — |
| Operating margin | −18,127.6% | −10,966.4% | −55,450.7% | — | — |
| Net income | −$15.7M | −$14.3M | −$20.7M | −$10.6M | −$9.8M |
| Net margin | −18,059.3% | −10,865.7% | −54,789.7% | — | — |
| Diluted EPS | −$0.14 | −$7.11 | −$9.18 | −$47.88 | −$4.56 |
| Cash | |||||
| Cash from operations | −$13.5M | −$15.2M | −$7.3M | −$8.6M | −$9.2M |
| Capital expenditure | $0.0M | $0.1M | — | — | — |
| Free cash flow | −$13.5M | −$15.4M | — | — | — |
| FCF margin | −15,533.4% | −11,677.6% | — | — | — |
| Share count change | 99.7% | −98.2% | 12.0% | −90.2% | 877.4% |
| Debt and strength | |||||
| Cash and short-term investments | $27.3M | $11.4M | $3.5M | $0.9M | $8.4M |
| Deposits | $0.0M | $0.0M | — | — | — |
| Shareholders' equity | $26.5M | $13.0M | $3.2M | −$0.2M | $8.3M |
| Current ratio | 19.2x | 9.0x | 2.1x | — | — |
| Interest coverage | −998.2x | −955.0x | −683.2x | −354.3x | −11.9x |
| Returns and quality | |||||
| Return on equity | −72.5% | −72.4% | −255.4% | −714.9% | −243.9% |
| Return on tangible equity | −59.3% | −109.8% | −652.0% | — | −118.9% |
| Piotroski F-score | — | 2 | 1 | — | — |
| Altman Z'' | −1.5 | −34.1 | −159.1 | — | — |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
1 insider
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Oragenics Inc · OGEN
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.40 a share, the company is worth $1.8M: 0.4 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001174940). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.